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Abstract
Background: Identification of patient-related factors associated with Health-Related Quality of Life (HRQoL) and
Quality of Life (QoL) at the start of treatment may identify patients who are prone to a decrease in HRQoL and/or
QoL resulting from chemotherapy. Identification of these factors may offer opportunities to enhance patient care
during treatment by adapting communication strategies and directing medical and psychological interventions. The
aim was to examine the association of sociodemographic factors, personality traits, and depressive symptoms with
HRQoL and QoL in patients with advanced-stage lung cancer at the start of chemotherapy.
Methods: Patients (n = 151) completed the State-Trait Anxiety Inventory (trait anxiety subscale), the Neuroticism-
Extraversion-Openness-Five Factor Inventory (NEO-FFI), the Center for Epidemiologic Studies Depression (CES-D), the
World Health Organization Quality of Life-BREF (WHOQOL-BREF), and the European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Simple linear regression analyses were
performed to select HRQoL and QoL associated factors (a P≤ 0.10 was used to prevent non-identification of
important factors) followed by multiple linear regression analyses (P ≤ 0.05).
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Results: In the multiple regression analyses, CES-D score (β = − 0.63 to − 0.53; P-values < 0.001) was most often
associated with the WHOQOL-BREF domains and general facet, whereas CES-D score (β = − 0.67 to − 0.40; P-values
< 0.001) and Eastern Cooperative Oncology Group (ECOG) performance status (β = − 0.30 to − 0.30; P-values < 0.001)
were most often associated with the scales of the EORTC QLQ-C30. Personality traits were not related with HRQoL
or QoL except for trait anxiety (Role functioning: β = 0.30; P = 0.02, Environment: β = − 0.39; P = 0.007) and
conscientiousness (Physical health: β = 0.20; P-value < 0.04).
Conclusions: Higher scores on depressive symptoms and ECOG performance status were related to lower HRQoL
and QoL in patients with advanced-stage non-small cell lung cancer. Supportive care interventions aimed at
improvement of depressive symptoms and performance score may facilitate an increase of HRQoL and/or QoL
during treatment.
Keywords: Cancer, Depression, Lung neoplasms, Oncology, Personality traits, Quality of life
Background
Patients with advanced-stage lung cancer have a poor
prognosis [1]. A 5 year survival of 6% was reported in
patients with stage IV non-small cell lung cancer accord-
ing to the datasets of the International Association for
the Study of Lung Cancer staging project [1]. In
addition, treatment may be associated with considerable
side effects, which can directly influence Health-Related
Quality of Life (HRQoL) [2] or even QoL in patients
with metastatic cancer. Therefore, treatment goals
should not be solely focused on survival benefits, but
also consider the effect on patients’ HRQoL and QoL.
HRQoL focusses on health and represents the impact
of disease and treatment on the feelings patients have
about their functional capabilities and well-being [3].
QoL assesses patients’ feelings (i.e., satisfied or bothered)
about their functioning and well-being in at least three
key areas (i.e., physical, psychological and social well-
being). It also evaluates a patient’s feelings related to
their environment (e.g., satisfaction with living condi-
tions) or spirituality (e.g., meaningfulness of personal
life). A recent study underscores the additional value of
spirituality for a patient’s well-being as it observed that
better cognitive and emotional functioning was seen in
cancer patients with higher spiritual well-being [4]. Pa-
tients with better global Health Status/QoL also had
higher spiritual well-being. In addition, besides the add-
itional assessment of a patient’s environment and spir-
ituality, a QoL instrument also contains positively
phrased items.
In studies that investigate new therapies in lung can-
cer, often HRQoL is evaluated and not QoL. These stud-
ies evaluate HRQoL to determine the impact of
treatment on cancer patients’ well-being. QoL may be
used in a similar manner and provides further informa-
tion as it enables a more comprehensive assessment of a
patients well-being than HRQoL. In a clinical setting, ap-
plication of HRQoL and QoL questionnaires may be
used to identify aspects of a patient’s health he/she is
bothered with. For instance, it may be used to monitor
the effects of treatment on a patient’s well-being. More-
over, HRQoL and QoL assessment may provide oppor-
tunities to apply interventions to improve HRQoL and
QoL. Regarding the questionnaires to evaluate HRQoL
and QoL in lung cancer: according to the definition of
the WHO, no lung cancer specific QoL questionnaire
has been developed. Some questionnaires are specifically
developed for lung cancer (e.g., European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30), Functional
assessment of Cancer Therapy-Lung), although they are
considered as a HRQoL instrument or even a Health
Status questionnaire in case of the EORTC QLQ-C30
given the emphasis on physical complaints rather than
well-being.
Several factors have been associated with HRQoL in
patients with lung cancer (i.e., age, performance status,
gender, education, and having a spouse/partner [5–7]) in
the past decades. In addition, in patients with cancer, de-
pressive symptoms are negatively related with HRQoL
[8, 9]. However, given that depressive symptoms also
have been negatively associated with spiritual well-being
[4], investigating the association between depressive
symptoms and QoL may provide further information
about the relation between depressive symptoms and a
patient’s well-being.
Personality has been associated with depressive symp-
toms in chronic illnesses [10, 11] and reduced emotional
HRQoL in heart failure patients [12]. In breast cancer,
high scores on certain personality traits (i.e., trait anxiety
and neuroticism) were associated with lower overall
QoL scores over time [13]. Considering these results, the
assessment of the association of personality traits with
HRQoL and QoL at the start of treatment in patients
with lung cancer may help identify patients who are
prone to low levels of HRQoL and/or QoL. Moreover,
taking knowledge of patient’s personality traits may be
of importance as they are linked with coping
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mechanisms. It may help personalize communication
strategies and the manner in which supportive care is
delivered. This may be of importance to increase, for in-
stance, treatment adherence.
However, studies that have investigated the relation
between the above mentioned factors (i.e., personality,
sociodemographic, clinical and psychological factors
(e.g., depressive symptoms)) and HRQoL and/or QoL in
patients with lung cancer are not reported. This is un-
fortunate since lung cancer patients are at risk to have
lower scores on functioning and well-being given their
disease, treatment-related adverse events, and life ex-
pectancy [14]. Moreover, a study by Temel and col-
leagues demonstrated that early palliative care in newly
diagnosed lung cancer patients improved HRQoL and
depressive symptoms at 12 and 24 weeks after treatment
commenced [15]. Therefore, knowledge of which factors
are associated with HRQoL and QoL prior to or at the
start of treatment may be worthwhile, because these fac-
tors may require additional care in individual patients
during treatment.
Contemplating on these considerations, we aimed to
evaluate to which extent depressive symptoms and per-
sonality traits solely and among variables related with
HRQoL (i.e., age, performance status, gender, education,
and having a spouse/partner [5–7]) are associated with
HRQoL and QoL in patients with advanced-stage lung
cancer prior to or at the start of treatment. We expected
depressive symptoms to be associated with lower scores
on HRQoL [8, 9] and QoL. In addition, we estimated
neuroticism and trait anxiety to be associated with de-
creased HRQoL and QoL scores [13].
Methods
Study population
PERSONAL is a prospective observational multi-center
cohort study of patients with stage IIIB or IV non-
squamous non-small cell lung cancer and unresectable
mesothelioma receiving pemetrexed. The present study
is part of PERSONAL. PERSONAL aims to study the
pharmacokinetic and pharmacologic effects of peme-
trexed. In addition, patient reported outcomes are mea-
sured. Patients were recruited from October 2012 to
November 2014 from three teaching hospitals (Erasmus
University Medical Center, Amphia Hospital and Sint
Franciscus Gasthuis hospital) and a regional hospital
(Bravis hospital). Patients were enrolled if they met the
following criteria: they were aged 18 years or older, had
a cytological or histological confirmed diagnosis of stage
IIIB or IV non-squamous non-small cell lung cancer or
unresectable malignant pleural mesothelioma, and
started treatment with pemetrexed in combination with
cisplatin or carboplatin as either first line or with peme-
trexed monotherapy as second line. Patients were
excluded if they were not able to read Dutch or could
not complete the questionnaires because of a physical or
mental condition. Eligibility was checked by two physi-
cians dedicated to the project. Informed consent was ob-
tained from all individual participants included in the
study. All procedures were in accordance with the eth-
ical standards of the institutional review board of the
Erasmus University Medical Center in Rotterdam, The
Netherlands (approval number MEC-2012-232) and with
the 1964 Helsinki declaration and its later amendments
or comparable ethical standards.
Procedures
All questionnaires were administered during consulta-
tions or by mail and completed after diagnosis and
just before or at the first day of the first cycle of
chemotherapy. Patients were asked once to complete
the questionnaires and not repeatedly to prevent that
they could feel obliged to comply to the researchers’
request. In addition, we collected sociodemographic
information (i.e., age, gender, educational level, ethni-
city, employment, partner status) and clinical informa-
tion (i.e., cancer stage, type of tumour, line of
therapy, and the Eastern Cooperative Oncology Group
(ECOG) performance status) from the hospital elec-
tronic information records and during regular
consultations.
Study measures
Quality of life
The World Health Organization Quality of Life-BREF
questionnaire (WHOQOL-BREF) is a cross-cultural and
generic QoL instrument [16]. The WHOQOL-BREF
comprises 24 items divided over four domains plus two
general facet items describing overall QoL and general
health. Items are scored on a Likert-scale from one
(worst QoL) to five (best QoL). The domains represent
physical health (seven items), psychological health (six
items), social relationships (three items) and environ-
ment (eight items). Examples of items are: How satisfied
are you with your capacity for work? (physical health);
How safe do you feel in your daily life? (psychological
health); How satisfied are you with your personal rela-
tionships? (social relationships); How satisfied are you
with your transport? (environment). WHOQOL-BREF
domains are scored on a 4–20 scale and the general
facet on a 2–10 scale with higher scores indicating better
QoL [16, 17]. The WHOQOL-BREF has satisfactory psy-
chometric properties in patients with lung cancer [18],
chronic diseases and other cancer types [16], except for
the social relationships domain (i.e., relatively low Cron-
bach’s alpha < 0.70).
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Health-related quality of life
The European Organization for Research and Treatment
of Cancer-Quality of Life Questionnaire-Core 30
(EORTC-QLQ-C30) is a cancer specific HRQoL instru-
ment originally developed in patients with lung cancer
[19]. It consists of 30 items and incorporates a global
Health Status/QoL scale, five functional scales and 13
items assessing symptoms or problems. The functional
scales represent physical functioning (five items), cog-
nitive functioning (two items), emotional functioning
(four items), role functioning (two items), and social
functioning (two items). Examples of items are: Do
you have trouble taking a long walk? (physical func-
tioning); Have you had difficulty remembering things?
(cognitive functioning); Did you feel depressed? (emo-
tional functioning); Has your physical condition or
medical treatment interfered with your family life?
(role functioning); Has your physical condition or
medical treatment interfered with your social activ-
ities? (social functioning). EORTC QLQ-C30 domains
are scored on a 0–100 scale, with higher scores on
the functional scales being indicative of better
HRQoL, whereas higher scores on the symptom scales
represent worse symptoms [19]. The EORTC has
demonstrated acceptable psychometric properties [20].
Personality traits
The State-Trait Anxiety Inventory (STAI) questionnaire
assesses state and trait anxiety [21]. We used the 10-
item STAI trait anxiety subscale (short version), which
was developed in women suspected with breast cancer
and breast cancer survivors [22]. Trait anxiety refers to
the tendency to respond to threatening situations with
increased anxiety intensity [13]. It is considered to be a
personality factor. Items are scored on a four-point scale
ranging from one (almost never) to four (almost always).
An example of an item is: I worry too much over some-
thing that really doesn’t matter. A score of ≥ 22 is indi-
cative for high trait anxiety [22]. The original Dutch
translation of the STAI [21, 23] and the 10-item subscale
itself [22] have good psychometric properties.
The 60-item Neuroticism-Extraversion-Openness-Five
Factor Inventory questionnaire (NEO-FFI) assesses per-
sonality based on the Five Factor Model [24–26]. It de-
scribes neuroticism, extraversion, openness to
experience, agreeableness, and conscientiousness. Neur-
oticism measures emotional stability. Extraversion as-
sesses the level to which orientation, energy and
attention are focused on the outside world instead of the
inner world. Openness reflects to an open attitude to-
wards experiences, beliefs and, people. Agreeableness re-
lates to a person’s level of being empathic, cooperative,
and considerate. Conscientiousness refers to the level of
being careful, diligent, and orderly. Items are scored on
a five-point scale with scores ranging from one (totally
disagree) to five (totally agree). Examples of items are: I
often feel inferior to others (neuroticism); I laugh easily
(extraversion); Once I find the right way to do some-
thing, I stick to it (openness); I try to be courteous to
everyone I meet (agreeableness); I keep my belongings
clean and neat (conscientiousness). The NEO-FFI has
good psychometric properties in patients with multiple
sclerosis [27] and has been used in patients with cancer
[28, 29]. For this study the raw scores of the NEO-FFI
domains were used.
Depressive symptoms
The Center for Epidemiologic Studies Depression
Scale (CES-D) is a 20-item questionnaire which evalu-
ates depressive symptoms [30]. We used the 16-item
version of the CES-D, in which the four positively
formulated items of the original CES-D are removed
[31, 32] since they lacked validity and did not corres-
pond well with the definition of depressive symptoms.
Items are scored on a four-point scale with scores
ranging from zero (rarely) to three (mostly). An ex-
ample of an item is: I felt that people dislike me. The
CES-D has good psychometric properties in cancer
patients [31, 33, 34].
Statistics
Patient characteristics between patients who completed
the questionnaires and those who did not were com-
pared with Fisher’s exact test and the independent T-
test.
Given the sample size of 151 patients, simple linear re-
gression analyses were performed as a minimal sample
size of 50 + 8m (in which m is the number of predictors)
is recommended [35]. Analyses were conducted for
sociodemographic variables (i.e., age, gender, ethnicity,
education, employment, partner status), ECOG perform-
ance status, CES-D score, STAI Trait subscale score, and
NEO-FFI subscale scores to identify possible factors as-
sociated with the WHOQOL-BREF domains and
EORTC QLQ-C30 scales. To prevent non-identification
of important variables by using a more strict alpha of ≤
0.05, variables with an alpha of ≤ 0.10 were selected as
possible predictors [36, 37].
With the variables associated with the WHOQOL-
BREF domains and EORTC QLQ-C30 scales according
to the simple linear regression analyses, multiple linear
regression analyses were performed. An alpha of ≤ 0.05
was used to identify significant factors in the multiple
linear regression analyses.
To contribute to statistical power several actions were
taken. Firstly, a priori hypotheses were formulated ac-
cording to the literature that we aimed to test in a
homogenous patient population to minimise variability
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in the outcome measure of interest. Secondly, a recom-
mended rule of thumb was used to calculate sample size
[35] and patients were encouraged by the investigators
to complete questionnaires to minimise the number of
dropouts. Lastly, to minimise the risk for a type I error
we applied Benjamini-Hochberg correction to adjust for
multiple analyses.
Furthermore, to confirm that the results of our
multivariable analyses were supported by sufficient
statistical power, we performed a post-hoc power-
analysis. Given an alpha of 0.05, a total of no more
than nine factors for each multivariable model, and
151 patients, we were able to find an effect size (i.e.,
partial R2) of 3.98%. This means that the analyses
were sufficiently powered to detect factors able to ex-
plain at least 3.98% variation in a HRQoL/QoL do-
main/scale score.
All analyses were performed using IBM SPSS Statistics
for Windows version 21.0.
Results
Patient characteristics
Figure 1 demonstrates the selection of patients. In total,
151 patients were used for analyses with the WHOQOL-
BREF and 150 patients for analyses with the EORTC
QLQ-C30. 89% of patients completed all domains of all
questionnaires. Table 1 summarizes the patient charac-
teristics of the included patients and the 26 patients who
did not complete any of the questionnaires. In general,
reasons for non-completion of questionnaires were re-
lated to the stress patients experienced resulting from a
diagnosis of advanced-stage lung cancer, the near start
of chemotherapy, and a poor prognosis. These patients
did not differ from the 151 included patients according
to the age, gender, ethnicity, employment, partner status,
cancer stage, tumour type, and line of therapy, except
for performance status. The proportion of patients with
a performance status of two or higher was larger in the
patients that were not available for the analyses than the
Enrolled patients
N=199
Eligible patients for inclusion 
and completion of 
questionnaires
N=177 
Patients who completed the 
questionnaires
WHOQOL-BREF N=151
EORTC QLQ-C30 N=150
Patients not treated with 
chemotherapy
N=4
Patients that did not complete 
any of the questionnaires
N=26
Patients staged with IIA, IIB, or 
IIIA and/or who received third 
line, adjuvant or neoadjuvant 
chemotherapy
N=18
Patients excluded
N=0
Fig. 1 Selection of patients. Abbreviations: N, number of patients; WHOQOL-BREF, World Health Organization Quality of Life-BREF questionnaire;
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
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included patients. WHOQOL-BREF domain scores,
EORTC QLQ-C30 scale score, personality scale scores
and CES-D scores are summarized in Table 2.
Linear regression analyses
Results of the simple linear regression analyses for each of
the HRQoL and QoL domains/scales are demonstrated in
Table 3 (see also Online Resource 1). Table 4 demon-
strates the multiple linear regression analyses for the
WHOQOL-BREF domains and general facet. After
Benjamini-Hochberg correction, CES-D score was nega-
tively associated with the general facet and with the phys-
ical and psychological health domains. For the EORTC
QLQ-C30 scale scores, CES-D score was negatively associ-
ated with the functioning scales and the global Health Sta-
tus/QoL score (Table 5). All of the standardized betas for
the significant associations between CES-D score and the
domains/scales of the WHOQOL-BREF and EORTC
Table 1 Characteristics of study population
Characteristic Patients who completed questionnaires (N = 151) Patients who did not complete any questionnaire (N = 26) Pa
Age, yearsb
Mean (SD) 63.3 (9.1) 63.7 (8.7) 0.85
Min, max 37, 83 47, 80
Gender
Male 82 (54.3) 12 (46.2) 0.53
Ethnicity
White / Caucasian 142 (94.0) 25 (96.2) 1.00
Other 9 (6.0) 1 (3.8)
Educationc
Low 113 (74.8)
High 32 (21.2)
Unknown 1 (0.7) 26 (100.0)
Employmentb
Yes 38 (25.2) 1 (3.8) 0.26
No 112 (74.2)
Unknown 1 (0.7) 25 (96.2)
Partner statusb
Partner 122 (80.8) 1 (3.8) 1.00
No partner 28 (18.5)
Unknown 1 (0.7) 25 (96.2)
Cancer stageb
Locally advanced (IIIB) 19 (12.6) 2 (7.7) 0.76
Metastatic (IV) 124 (82.1) 23 (88.5)
Other 8 (5.3) 1 (3.8)
Type of tumorb
Adenocarcinoma 136 (90.1) 24 (92.3) 1.00
Large cell carcinoma, mesothelioma, other 15 (9.9) 2 (7.7)
Line of therapy
irst 140 (92.7) 22 (84.6) 0.24
econd 11 (7.3) 4 (15.4)
ECOG performance statusb
Grade 0 or 1 135 (89.4) 18 (69.2) 0.02
Grade 2 or higher 14 (9.3) 7 (26.9)
Unknown 2 (1.3) 1 (3.8)
Values are given in numbers (percentages) unless stated otherwise. aP-values reflect differences between patients who completed any questionnaire and
those who did not
bMeasured at the start of treatment with chemotherapy
cLow education: persons whose highest level of education is primary education, lower general education or lower vocational education. High education:
persons whose highest level of education is higher general education, higher vocational education or university.
Abbreviations: N number of patients, SD standard deviation, ECOG Eastern Cooperative Oncology Group (ECOG)
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QLQ-C30 were larger than 0.40. After Benjamini-
Hochberg correction, ECOG performance status was
negatively associated with the physical and role function-
ing scale scores of the EORTC QLQ-C30 and with the
physical health domain of the WHOQOL-BREF. For the
NEO-FFI personality traits, only a positive association be-
tween the conscientiousness scale and the physical health
domain of the WHOQOL-BREF was observed. Trait anx-
iety was negatively associated with environment (WHO-
QOL-BREF) and positively with role functioning (EORTC
QLQ-C30). For the WHOQOL-BREF explained variances
ranged from 0.20 to 0.55 and for the EORTC QLQ-C30
from 0.36 to 0.66.
Discussion
Due to a diagnosis of cancer and potential treatment-
related side effects advanced-stage lung cancer patients
are at risk to experience a decrease in HRQoL and QoL
after they start with treatment. Physicians are aware of this
[38] and try to optimize HRQoL and QoL. Evaluation of
factors associated with HRQoL and QoL at the start of
treatment may provide opportunities to prevent further
deterioration of those areas of HRQoL and/or QoL that
are related to these factors. To our knowledge, this pro-
spective multi-centre observational study is the first that
aimed to investigate if personality traits, depressive symp-
toms, and sociodemographic factors are associated with
HRQoL and QoL in patients with advanced-stage lung
cancer prior to or at the start of treatment. Considering
that HRQoL merely reflects those components of QoL
that are influenced by treatment and disease [3], we
choose to include a QoL measure (i.e., WHOQOL-BREF)
as well since this offers additional information describing
patients’ feelings about their environment and spirituality/
existentiality. We observed that higher levels of depressive
symptoms were associated with decreased HRQoL and
QoL except for social relationships and environment.
Given the associations with both HRQoL and QoL and
the fact that depressive symptoms are common [1, 2], our
results emphasize the importance of physicians’ awareness
for depressive symptoms in patients with advanced-stage
lung cancer.
Compared to a recent study in Dutch patients with
lung cancer, we observed a lower general health/QoL
score (i.e., facet score of 7.0 (SD 1.4) versus 5.8 (SD 1.7)
in this study) [39]. Probably this is due to the inclusion
of solely patients with locally-advanced and metastatic
lung cancer in our study whereas the referred study in-
cluded patients with all stages of lung cancer with stage
I and II comprising 45% of the study population. How-
ever, this difference in QoL underscores the need for the
development of interventions to improve QoL in pa-
tients with advanced-stage lung cancer. In patients with
breast and prostate cancer, it was reported that an easy-
to-use well-being intervention (i.e., recording of positive
experiences in a diary, listening to a mindfulness CD,
planning a pleasurable activity) could positively influence
overall QoL (i.e., facet score WHOQOL-BREF) [40].
Table 2 WHOQOL-BREF, EORT QLQ-C30, NEO-FFI, CES-D, and STAI trait scale/domain scores
Questionnaire Scale/domain N Median Mean (SD) Min, max (IQR) Range
WHOQOL-BREF Physical health 145 13.1 12.9 (3.1) 4.0, 20.0 (4.6) 16
Psychological health 145 14.7 14.5 (2.4) 9.3, 20.0 (3.3) 10.7
Social relationships 145 16.0 16.3 (2.5) 8.0, 20.0 (3.3) 12
Environment 145 16.0 15.9 (2.2) 10.0, 20.0 (3.0) 10
General facet 142 6.0 5.8 (1.7) 2.0, 10.0 (2.0) 8
EORTC QLQ-C30 Physical functioning 150 66.7 68.1 (24.1) 6.7, 100.0 (33.3) 93.3
Cognitive functioning 142 83.3 80.3 (23.1) 0.0, 100.0 (33.3) 100
Emotional functioning 142 75.0 67.3 (24.0) 0.0, 100.0 (33.3) 100
Role functioning 149 66.7 55.1 (32.8) 0.0, 100.0 (50.0) 100
Social functioning 142 83.3 71.5 (27.0) 0.0, 100.0 (50.0) 100
Global Health Status/QoL 142 58.3 54.8 (25.5) 0.0, 100.0 (41.7) 100
NEO-FFI Neuroticism 137 28.0 28.1 (7.4) 12.0, 53.0 (8.5) 41
Extraversion 133 40.0 40.4 (6.6) 22.0, 56.0 (9.5) 34
Openness 134 34.0 34.3 (5.9) 20.0, 50.0 (7.3) 30
Agreeableness 139 43.0 42.8 (5.0) 29.0, 54.0 (6.0) 25
Conscientiousness 134 47.0 47.1 (5.7) 34.0, 60.0 (9.3) 26
STAI Trait anxiety 147 17.0 17.7 (5.3) 10.0, 34.0 (8.0) 24
Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, EORTC QLQ-C30 European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30, NEO-FFI, Neuroticism-Extraversion-Openness-Five Factor Inventory, CES-D Center for Epidemiologic Studies
Depression Scale, STAI State-Trait Anxiety Inventory, N number of patients, SD standard deviation, IQR inter quartile range
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Moreover, in a study with Iranian breast cancer patients
an intervention of eight mindfulness group-based train-
ing sessions resulted in improved overall QoL and less
depressive symptoms, anxiety, and stress compared to
the control group [41]. Regarding HRQoL, a Cochrane
review reported that exercise training resulted in im-
proved global HRQoL although this was not observed
for physical functioning. Also the risk of bias in all six
included studies was high and the quality of evidence for
the outcomes was low [42]. In another study, Nabilone,
a synthetic cannabinoid used to improve caloric intake,
resulted in improved aspects of HRQoL (i.e., role func-
tioning, emotional functioning, and social functioning)
[43]. Unfortunately, all of the mentioned studies are
hampered by their design and relatively small sample
sizes, although their results suggest that the develop-
ment of interventions to improve HRQoL and QoL
could be beneficial for patients with advanced-stage can-
cer. Therefore, randomized studies with larger patient
populations are needed that could further develop and
test the additional value of interventions designed to im-
prove HRQoL and QoL. Such studies should particularly
aim their proposed interventions at improving perform-
ance status and depressive symptoms as, according to
our results, these factors contribute the most to HRQoL
and QoL.
In the present study CES-D score was related to all
HRQoL scales and QoL domains, except the
WHOQOL-BREF domains social relationships and en-
vironment. Previousy, the CES-D score has been related
with HRQoL and QoL in breast cancer [44, 45]. In the
study by Hyphantis and colleagues, amongst others, age,
stage of cancer, levels of anxiety, depressive symptoms,
and use of repression were related with QoL [45]. In line
with the results of the present study, they did not ob-
serve a relationship between social relationships and
CES-D score. However, in another study in lung cancer
patients significant depressive symptoms were associated
with decreased QoL, including social relationships and
environment [46]. Reasons for this may be related to dif-
ferences in patient characteristics or the relatively large
time since diagnosis (i.e., at least 20 months) that pa-
tients completed the questionnaires compared to our
study. In our study, patients were at the start or prior to
treatment whereas in the study by Gu et al. patients
already received treatment for some time [46]. Treat-
ment may have had an impact on the relation between
depressive symptoms and QoL.
NEO-FFI personality traits were not associated with
HRQoL and QoL in this study, except for conscientious-
ness. Trait anxiety was associated with only two HRQoL
and QoL scales/domains, namely role functioning and
environment. Considering that CES-D score was associ-
ated with almost all HRQoL and QoL scales/domains,
we hypothesized whether the absent effect of personality
traits on HRQoL and QoL was influenced by CES-D
Table 4 Results of the multivariable regression analyses for the WHOQOL-BREF (p < 0.05)
Independent variables N B SE β P-value Corrected P-valuea 95% CI for B R
2
General facet
Age 117 −0.041 0.015 −0.232 0.006 0.024 −0.070, − 0.012 0.402
CES-D −0.133 0.021 −0.625 < 0.001 < 0.001 −0.175, − 0.091
Physical health
ECOG: 0 to 1 versus 2 or higher 117 −2.747 0.751 −0.262 < 0.001 < 0.001 −4.234, −1.259 0.517
CES-D −0.221 0.035 −0.542 < 0.001 < 0.001 −0.291, − 0.151
NEO-FFI conscientiousness 0.111 0.045 0.201 0.016 0.043 0.021, 0.200
Psychological health
CES-D 117 −0.163 0.025 −0.534 < 0.001 0.000 −0.213, − 0.113 0.554
Social relationships
Gender 119 1.107 0.467 0.222 0.020 0.080 0.181, 2.032 0.204
Partner status: no partner versus having a partner 1.428 0.588 0.216 0.017 0.080 0.262,
2.594
Environment
CES-D 116 −0.063 0.028 −0.224 0.026 0.091 −0.118,
− 0.008
0.375
STAI Trait −0.163 0.049 −0.392 0.001 0.007 −0.259,
− 0.066
aBenjamini-Hochberg method was used to correct P-values
Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, N number of patients, B unstandardized beta, SE standard error, β
standardized beta, CI confidence interval, R2 explained varriance, CES-D Center for Epidemiologic Studies Depression Scale, ECOG Eastern Cooperative Oncology
Group, NEO-FFI Neuroticism-Extraversion-Openness-Five Factor Inventory questionnaire, STAI, State Trait Anxiety Inventory
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score. Therefore, new analyses were performed without
CES-D score. For the WHOQOL-BREF, trait anxiety
was associated with not only the environment domain,
but also with physical and psychological health. Instead
of an association with role functioning, trait anxiety was
associated with the EORTC QLQ-C30 scales emotional
functioning and social functioning. Previously, similar
results have been observed. In a study with Turkish
colorectal patients that received chemotherapy, patients
with low trait anxiety (scale score < 45) had better
HRQoL for all EORTC QLQ-C30 functioning scales and
the global QoL/HS scale [47]. Another study in women
under follow-up for breast cancer observed that the level
of anxiety according to the total STAI score was related
with the emotional functioning scale of the EORTC
QLQ-C30 [48]. As such, our observations and the results
of these studies emphasize the importance of trait anx-
iety as a factor associated with HRQoL and QoL, espe-
cially in the absence of depressive symptoms and may
provide professionals opportunities to personalize the
way they provide supportive care (e.g., by adapting com-
munication strategies, stimulating effective coping mech-
anisms). Given that neuroticism has been linked with
depressive symptoms in patients with lung cancer [49],
we expected that the effect of neuroticism was masked
by CES-D score. However, after removal of CES-D score
from the models, neuroticism was not associated with
any HRQoL scale or QoL domain. Furthermore, none of
Table 5 Results of the multivariable regression analyses for the EORTC QLQ-C30 (p < 0.05)
Independent variables N B SE β P-value Corrected P-valuea 95% CI for B R
2
General Health Status/Quality of Life
Employment: yes versus no job 116 10.405 4.358 0.183 0.019 0.076 1.764,
19.045
0.417
CES-D −2.062 0.314 −0.627 < 0.001 < 0.001 −2.684,
−1.439
Physical functioning
Employment: no versus having a job 117 10.684 3.885 0.204 0.007 0.021 2.981,
18.386
0.453
ECOG: 0 to 1 versus 2 or higher −23.586 5.958 −0.304 < 0.001 < 0.001 −35.398,
−11.775
CES-D −1.357 0.284 −0.449 < 0.001 < 0.001 −1.921,
− 0.793
Role functioning
ECOG: 0 to 1 versus 2 or higher 120 −30.890 7.975 −0.299 < 0.001 < 0.001 −46.692,
−15.088
0.414
CES-D −2.197 0.384 −0.542 < 0.001 < 0.001 − 2.957,
−1.437
STAI Trait 1.840 0.687 0.295 0.009 0.024 0.479,
3.201
Emotional functioning
CES-D 117 −2.044 0.222 −0.668 < 0.001 < 0.001 −2.483,
−1.604
0.655
Cognitive functioning
Educational level: low versus high 129 9.344 4.060 0.170 0.023 0.069 1.307,
17.382
0.359
CES-D −1.572 0.274 −0.536 < 0.001 < 0.001 −2.114,
− 1.030
Social functioning
Partner status: no partner versus having a partner 116 −12.786 5.817 −0.174 0.030 0.090 −24.318,
−1.253
0.370
ECOG: 0 to 1 versus 2 or higher −16.748 7.367 −0.188 0.025 0.090 −31.354,
−2.141
CES-D −1.394 0.348 −0.401 < 0.001 < 0.001 −2.085,
− 0.704
aBenjamini-Hochberg method was used to correct P-values
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, N number of patients, B
unstandardized beta, SE standard error, β standardized beta, CI confidence interval, R2 explained varriance, CES-D Center for Epidemiologic Studies Depression
Scale, ECOG Eastern Cooperative Oncology Group, STAI State Trait Anxiety Inventory
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the other NEO-FFI personality traits were associated
with HRQoL and QoL. In contrast, type D personality
has previously been related with decreased HRQoL in
patients with cancer [50, 51]. Given that in the past type
D personality has been positively correlated with neur-
oticism and negatively with extraversion in healthy indi-
viduals [52, 53], it remains unclear why neuroticism or
extraversion were not related with HRQoL or QoL in
the present study. A reason for this may be that type D
personality is more related with HRQoL and QoL than
the NEO-FFI personality traits as was observed in female
patients with ulcerative colitis [53]. Unfortunately, other
studies that could further elucidate this lack of signifi-
cance between NEO-FFI personality traits and HRQoL
and QoL in cancer patients have not been reported.
Therefore, the effect of personality traits according to
the NEO-FFI on HRQoL and QoL remains unclear in
patients with lung cancer.
We observed an unexpected result during the multiple
regression analyses. First, the direction of the beta of the
STAI trait scale in the analysis with role functioning as
dependent variable was positive. This is in contrast with
previous results. In a study with patients with chronic
diseases trait anxiety was negatively associated with role
physical and role emotional score of the Short-Form 36,
a HRQoL questionnaire [54]. Moreover, in colorectal
survivors anxiety was significantly associated with lower
role functioning over time [55]. To analyse whether this
finding was due to multi-collinearity, we correlated the
STAI trait scale with the other variables that were asso-
ciated with role functioning (i.e., CES-D score and
ECOG performance status). We observed a strong and
positive correlation with CES-D score. This could indi-
cate that the effect of trait anxiety is explained by CES-D
score. Second, we observed an, at first glance, unex-
pected negative direction of the beta of partner status in
the analysis with social functioning as dependent vari-
able. However, in a study with advanced-stage cancer
patients a similar result was observed [5]. Another study
reported also lower social functioning in married/cohab-
ited patients [6]. Moreover, as only weak correlations
were observed between partner status and ECOG per-
formance status, CES-D score and age, indications for
multi-collinearity were not found.
Some limitations of this study have to be addressed.
First, because of the cross-sectional nature of our data,
we cannot conclude whether depressive symptoms are a
cause of decreased HRQoL and QoL or a consequence,
or whether both depressive symptoms and HRQoL and
QoL are caused by a third variable. Therefore, ideally,
our findings should be cross validated in another study
as the observed results may merely describe idiosyncra-
sies of the data at hand. Second, the relatively small
number of patients may have influenced our results.
This could have resulted in the non-identification of var-
iables associated with HRQoL and QoL. For this reason,
the 10 patients with mesothelioma (i.e., 6.6% of the total
patient population) were also used for the analysis.
Given that the mesothelioma patients received the same
chemotherapy as the other patients, we did not expect
differences in terms of number and severity of adverse
events between the mesothelioma and the lung cancer
patients. Moreover, prognosis in patients with mesotheli-
oma is also limited. Therefore, considering these similar-
ities it was expected that the use of the data of the 10
patients for our analyses would not interfere with the
observations of this study. To verify this assumption, the
multivariable analyses were rerun without the 10 meso-
thelioma patients. After Benjamini-Hochberg correction,
we observed the same results except that conscientious-
ness was no longer identified as a predictor of physical
health. Third, there is a potential response bias in that
possibly the most optimistic of patients or those who
had a caregiver who could help with the survey were the
ones who returned the questionnaires. Fourth, we re-
lated the total CES-D score with HRQoL and QoL.
Given that the CES-D contains some items that may
demonstrate an overlap with the domains/scales of the
WHOQOL-BREF and EORTC QLQ-C30, this could
partly explain the observed associations between CES-D
score and these domains/scales. However, it was previ-
ously demonstrated that just low to moderate correla-
tions exist between the CES-D and the WHOQOL-
BREF [56]. Moreover, in the same article results of a
Rasch-analysis were reported that demonstrated that just
11 items of the WHOQOL-BREF demonstrated differen-
tial item functioning regarding the presence of depres-
sion meaning that at a same level of QoL patients with a
depression scored these 11 items differently than those
without a depression. Removing these 11 items from our
analyses would hamper comparing our results with other
studies as most studies in cancer do not use an adapted
version of the WHOQOL-BREF. In addition, given that
the constructs of these questionnaires differ, this also
contributes to their utility apart from each other. Fifth,
the CES-D also contains some items that demonstrate
an overlap with physical symptoms of cancer patients. In
potential, this could also partly explain the observed as-
sociations between CES-D score and HRQoL and QoL.
However, in a study evidence for removing somatic
items from the CES-D in cancer patients could not be
confirmed (1). In addition, the definition of depressive
symptoms includes symptoms like weight loss and fa-
tigue besides symptoms associated with a negative affect.
Moreover, to not include the scores of the somatic items
in the total CES-D score, would hamper comparing our
results with other studies as many studies in cancer ex-
ploring depressive symptoms use a total CES-D score.
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This study has some strengths too. We are the first to
investigate the association between sociodemographic
variables, clinical variables, depressive symptoms, and
personality traits with both HRQoL and QoL. Moreover,
although our sample size was relatively small, we de-
scribe results of a prospective study with a homogeneous
patient population. Also the application of well-
recognized standardized questionnaires, the multi-center
prospective design of this study, and the inclusion of pa-
tients that resemble clinical practice strengthen our
findings.
Conclusions
In conclusion, our results demonstrated that health care
professionals are recommended to have high awareness
during consultations for patients with depressive symp-
toms and those with an ECOG performance status of
two or higher at the start of treatment. This is of im-
portance as these factors may indicate low levels of
HRQoL and QoL of patients. Moreover, merely assessing
HRQoL and QoL and not depressive symptoms or per-
formance status may be insufficient. For instance if psy-
chological health is low, one has to further investigate if
this is caused by anxiety or depressive symptoms or an-
other reason given that treatment may differ according
to the cause of the low psychological health. Therefore
screening for the presence of these two factors before
treatment is initiated (e.g., by means of an e-tool that
screens for depressive symptoms, consequently reporting
performance status during consultations) may be worth-
while. Additional care (e.g., referral to a psychologist,
physiotherapist, medication, etc) aimed at improving
these factors can then be provided.
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